Analyst picks & changes
By BC Staff | Mar 19, 2007 | 7:00 AM GMT
Analyst picks & changes
| Company | Bank | Analyst | Coverage | Rating | Wk chg | 3/16 cls |
| Adventrx (ANX) | ThinkEquity | Vinny Jindal | New | Buy | -5% | $1.98 |
| Jindal set a $5 target. He sees the company's CoFactor (ANX-510) as a potential target for partnering, and expects results from a Phase IIb trial comparing the compound to leucovorin in metastatic colorectal cancer in 2H07. The folate-based active metabolite of leucovorin is also in Phase III testing for metastatic colorectal cancer and in Phase II for advanced breast
|
Read the full 818 word article
